Novavax (NVAX) Revenue Growth (3y) (2013 - 2026)
Novavax (NVAX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 54.05% |
| 10 | Novavax | 1.24 Bn | 453.01 Mn | 108.82 Mn | 19.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.89% |
| Dec 31, 2025 | -25.61% |
| Sep 30, 2025 | -54.23% |
| Jun 30, 2025 | -2.00% |
| Mar 31, 2025 | -1.80% |
| Dec 31, 2024 | -26.48% |
| Sep 30, 2024 | -22.11% |
| Jun 30, 2024 | 11.71% |
| Mar 31, 2024 | -40.57% |
| Dec 31, 2023 | 1.37% |
| Sep 30, 2023 | 5.99% |
| Jun 30, 2023 | 128.58% |
| Mar 31, 2023 | 188.33% |
| Dec 31, 2022 | 243.53% |
| Sep 30, 2022 | 564.19% |
| Jun 30, 2022 | 281.18% |
| Mar 31, 2022 | 461.24% |
| Dec 31, 2021 | 231.00% |
| Sep 30, 2021 | 184.89% |
| Jun 30, 2021 | 202.44% |